Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15723380 | 0.68 | — | — | |
| SCHEMBL10181708 | 0.67 | LMNA (0.35) | LMNAMAPT | |
| SCHEMBL12570331 | 0.64 | LMNA (0.34) | LMNAMAPT | |
| SCHEMBL20351566 | 0.64 | ALDH1A1 (0.31) | MAPT | |
| SCHEMBL22342349 | 0.64 | ALDH1A1 (0.31) | MAPT | |
| SCHEMBL21338968 | 0.64 | LMNA (0.31) | LMNAMAPT | |
| SCHEMBL13139151 | 0.63 | — | — | |
| SCHEMBL13139133 | 0.63 | — | — | |
| SCHEMBL25464198 | 0.62 | — | — | |
| SCHEMBL21376417 | 0.62 | LMNA (0.33) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9309285-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | LMNA 1941/4885MAPT 3906/4885 |
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | LMNA 1857/4885MAPT 4006/4885 |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | LMNA 1941/4885MAPT 3906/4885 |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | LMNA 1857/4885MAPT 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.